The present disclosure describes immunogenic portions of Bordetella adenylate cyclase toxin (ACT), and neutralizing antibodies specific for such polypeptides. The antibodies can be used for diagnosis and anti-Bordetella therapies. Further provided are vaccine compositions including recombinant Bordetella adenylate cyclase toxin polypeptides.